華虹(01347)短線反彈機會來臨?技術面與窩輪牛熊證解讀
Ge Long Hui· 2025-05-19 11:43
Group 1 - Semiconductor stocks in Hong Kong, particularly Hua Hong Semiconductor (01347), have shown a rebound after a four-day decline, with a current price increase of 4.18% to HKD 31.15 [1] - Despite the rebound, the stock price remains below the Bollinger Band midline (HKD 34.28) and is testing important support levels on the weekly chart (HKD 31.35) [1] - Technical indicators present mixed signals, with key support levels at HKD 29.4 and HKD 26.4, while resistance levels are at HKD 33.8 and HKD 35.9 [3] Group 2 - The market sentiment is low, with many investors expecting the stock price to drop to the range of HKD 29-20, while a minority believes it could rise to HKD 33 [3] - In the derivatives market, Citigroup's call option (28354) is highlighted as an attractive bullish choice with a strike price of HKD 36.36 and a leverage of 3 times [3] - Other notable call options include Huatai's (16555) with a 3.2 times leverage and a current increase of 9.52%, and JPMorgan's (29035) with a higher strike price of HKD 38.93 and a leverage of 3.47 times [3] Group 3 - Bullish and bearish certificates are available, with JPMorgan's bullish certificate (55757) offering a leverage of 7.3 times and a recovery price of HKD 29, suitable for aggressive investors [6] - Conversely, JPMorgan's bearish certificate (55767) provides a leverage of 5.1 times with a recovery price of HKD 35.5, appealing to investors looking to short while managing risk [6]
603389,10连板;002190,9连板!多股高位狂飙
Zheng Quan Shi Bao· 2025-05-19 11:30
19日,沪指盘中窄幅震荡,北证50指数强势拉升;港股午后止跌回升,恒生指数一度翻红。 具体来看,沪指盘中窄幅震荡整理,深证成指、创业板指午后逐渐止跌,北证50指数涨超2%。截至收盘,沪指平收报3367.58点,深证成指跌0.08%报 10171.09点,创业板指跌0.33%报2032.76点,沪深北三市合计成交11191亿元,成交额和此前一日大致相当。 场内超3500股飘红,并购重组概念爆发,金利华电(300069)、天元宠物(301335)、光智科技(300489)等涨停;ST板块亦走强,*ST天喻(300205) 涨超11%,ST香雪(300147)涨近10%;航运概念延续强势,连云港、宁波海运(600798)、南京港(002040)斩获5连板;食品饮料、旅游餐饮等消费 股集体上扬,天味食品、巴比食品(605338)等涨停。值得注意的是,多只高位股继续飙升,*ST亚振(603389)(603389)斩获10连板,成飞集成 (002190)(002190)斩获9连板,利君股份(002651)(002651)9日斩获8个涨停板,中毅达(600610)(600610)再度涨停,年内累计大涨约280%。 港股方面 ...
5月19日电,阿里健康2024年营收306.0亿元人民币,预估302.7亿元人民币。
快讯· 2025-05-19 11:09
智通财经5月19日电,阿里健康2024年营收306.0亿元人民币,预估302.7亿元人民币;调整后净利润19.5 亿元人民币;毛利率24.3%,预估24.1%。 ...
零跑汽车(09863.HK)2025年Q1营收100.2亿元,上年同期34.86亿元。
快讯· 2025-05-19 11:08
零跑汽车(09863.HK)2025年Q1营收100.2亿元,上年同期34.86亿元。 ...
阿里健康:2025财年净利润同比增长62.2%
快讯· 2025-05-19 11:08
阿里健康公告,截至2025年3月31日止年度,公司收入实现稳定增长,总收入为305.98亿元人民币,同 比增长13.2%。报告期内净利润额为14.32亿元人民币,同比增长62.2%。调整后净利润额为19.5亿元人 民币,同比增长35.6%,调整后净利润率从5.3%提升至6.4%。报告期内,天猫健康平台业务持续稳健发 展,年度GMV保持稳健增长,年度活跃用户数持续提升。 ...
沪上阿姨升级果蔬茶增加膳食纤维,新茶饮迈入健康消费新时代
Nan Fang Du Shi Bao· 2025-05-19 11:00
新茶饮正在全面步入"健康升级时代"。近日,沪上阿姨即将在5月20日推出五款全新升级的"超级果蔬茶 系列",在膳食纤维含量上为消费者做"加法"。 同一时间,沪上阿姨还发布了《中国现制茶饮膳食营养升级白皮书》(以下简称《白皮书》),《白皮 书》是由权威机构中营惠营养健康研究院编撰、中国营养学会的营养健康研究院指导,通过科学全面的 阐述合理膳食和膳食营养平衡对人体生长、免疫和健康的重要性,结合消费者日益升级和个性化的健康 茶饮新需求,提出"每日健康+"全新理念,倡导面对不断升级的健康茶饮需求,以及行业出现的产品结 构高度趋同,营销手段陷入"品牌联名+价格战"循环等问题,通过产品创新、完善产业链标准,推动行 业健康可持续发展。可以看到,新茶饮行业从早前的"卷价格"开始"卷健康",茶饮品牌将更多注意力回 归到产品创新研发的本质上,重塑行业价值。 升级果蔬茶产品每瓶膳食纤维超5g 据了解,沪上阿姨此次焕新升级果蔬茶系列推出的产品包括羽衣火龙果高纤瓶、羽衣甘蓝纤体瓶、暗夜 玫瑰发光瓶、苦瓜不苦去火瓶、芭乐树番茄发光瓶这五款产品,每瓶膳食纤维均超5g,可以满足成人每 日所需20%-35%的膳食纤维。 在新茶饮行业深耕12年的 ...
【Fintech 周报】A股银行市值首破10万亿;恒生银行回应裁员风波;巴菲特Q1大笔卖出银行股
Sou Hu Cai Jing· 2025-05-19 10:49
Regulatory Dynamics - Seven departments, including the Ministry of Science and Technology and the People's Bank of China, jointly issued policies to accelerate the construction of a technology finance system, focusing on venture capital, monetary credit, capital markets, and technology insurance to support innovation [1] - The "Nansha Financial 30 Measures" were released to explore financial regulatory innovation and cooperation, aiming to enhance the uniformity, professionalism, and transparency of financial technology regulation [2] Industry Dynamics - Several banks have introduced limited-time offers, with cash installment rates dropping to as low as 2% to 4%, with examples including China Merchants Bank offering a 1.7-fold interest discount, resulting in an annualized rate as low as 2.76% for 12-month installments [3] - The A-share banking sector's market capitalization has surpassed 10 trillion yuan, with the China Securities Bank Index reaching a high of 7751.80 points, supported by high dividends and low valuations [3] - Over 40 banks have "disappeared" this year, with announcements of mergers and acquisitions, indicating a trend of consolidation in the banking sector [4][5] Corporate Dynamics - iYunBao completed a C-round financing, attracting Canada’s Sun Life Financial as a strategic investor, marking a significant investment in the insurance technology sector [10] - Hebei Bank's shares have faced multiple failed auctions, indicating challenges in attracting bidders despite a reported revenue increase of approximately 22% year-on-year [9] - Huayi Payment has submitted a new listing application to the Hong Kong Stock Exchange, marking its third attempt, with a reported revenue increase of 8.54% but a net profit decrease of 9.31% [11]
4天3板!002365再冲涨停创近期股价新高!
Zheng Quan Ri Bao Wang· 2025-05-19 10:47
本报记者 李万晨曦 东方财富数据显示,截至5月19日收盘,潜江永安药业股份有限公司(以下简称"永安药业",股票代码:002365)涨停, 股价报15.41元/股,创今年以来股价新高。永安药业当日主力资金净流入1.82亿元。 "永安药业此番股价大幅上扬,或与牛磺酸产品出口价格上涨相关。"中关村物联网产业联盟副秘书长袁帅在接受《证券日 报》记者采访时表示,中金在线数据显示,4月份医药级牛磺酸出口单价达8.9美元/公斤,食品级达6.89美元/公斤,价格显著上 涨。而永安药业作为牛磺酸行业的龙头,凭借规模优势与成本控制能力,在市场竞争中占据着有利地位。 福州公孙策公关咨询有限公司合伙人詹军豪在接受《证券日报》记者采访时表示,从市场环境层面来看,近期市场对牛磺 酸产业链关注度持续提升,保健品、宠物经济、化学原料药等相关概念板块整体表现活跃,板块联动效应为永安药业股价上涨 提供有力支撑。 | 15.41 | 9.99% 开通 | | --- | --- | | | 大单 | | | 1 | | | 当前 | | | 封单 | | | 最高 | | 1-4:01- | 涨停 | | | 兰 | | | 买2 | 这一涨势延 ...
出海速递 | 泡泡玛特越来越像爱马仕了/中国式出海:一部说走就走的史诗
3 6 Ke· 2025-05-19 10:28
Group 1 - The article discusses the new trends and historical context of the recent wave of Chinese companies going global, highlighting the internal logic behind this phenomenon [2] Group 2 - The U.S. Secretary of the Treasury indicated that if trade agreements are not reached within a 90-day tariff suspension period, tariffs will revert to "equivalent" levels, emphasizing the importance of negotiations with 18 key trading partners [8] - CATL's chairman stated that the penetration rate of electric heavy trucks in the domestic market is expected to reach 50% within three years, with a projected 10% in 2024 [8] - CATL plans to invest up to $225 million in an overseas private equity fund focused on carbon neutrality, with a target fund size of $1.5 billion [8] - Guoxuan High-Tech announced six new technologies, including a solid-state battery with a range of 1000 kilometers and a pre-production phase for its solid-state battery [9] - Changan Automobile's first overseas electric vehicle factory in Thailand has officially commenced production, with an investment of approximately 20 billion RMB [9] - Geely Auto has partnered with the National Bank of Egypt to provide locally assembled Emgrand models as official vehicles, with a local production rate exceeding 45% [9]
石药集团(01093.HK):CPO301获美国FDA授予第三项快速通道资格用于治疗NSCLC成年患者
Ge Long Hui· 2025-05-19 10:17
Group 1 - The core point of the article is that CSP301, a novel EGFR antibody-drug conjugate developed by the company, has received its third Fast Track designation from the FDA for treating advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) patients without EGFR mutations or other driver gene alterations who have progressed after platinum-based chemotherapy and anti-PD-(L)1 therapy [1][2] - CPO301 has previously received two Fast Track designations from the FDA, the first in June 2023 for treating EGFR-mutant metastatic NSCLC patients who have relapsed or are refractory after EGFR-targeted therapy, and the second in September 2024 for treating recurrent or metastatic squamous NSCLC patients with EGFR overexpression who have progressed after platinum-based chemotherapy and anti-PD-(L)1 therapy [1][2] - Lung cancer is the most prevalent and deadliest cancer globally, with approximately 2.5 million new cases and 1.8 million deaths annually, driven by activated EGFR gene mutations and overexpression of the EGFR protein [2] Group 2 - CPO301's Fast Track designations are based on encouraging clinical efficacy data, indicating its potential for greater activity compared to existing NSCLC and other cancer treatment options [2] - CPO301 is a humanized monoclonal antibody optimized from cetuximab and conjugated with topoisomerase I inhibitors, currently undergoing clinical studies in both China and the United States [2] - The Fast Track designation from the FDA will facilitate the development and registration process of CPO301 in the U.S. and globally [2]